Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31087909 | 1.00 | HRH3 (0.60) | HRH3MAPTL3MBTL1CRHBPCRHR2 | |
| SCHEMBL28408754 | 1.00 | HRH3 (0.60) | HRH3MAPTL3MBTL1CRHBPCRHR2 | |
| SCHEMBL26329663 | 1.00 | HRH3 (0.60) | HRH3MAPTL3MBTL1CRHBPCRHR2 | |
| SCHEMBL5520486 | 0.98 | HRH3 (0.57) | HRH3MAPTL3MBTL1CRHBPCRHR2 | |
| SCHEMBL9335578 | 0.95 | HRH3 (0.56) | HRH3MAPTL3MBTL1CRHBPCRHR2 | |
| SCHEMBL3345446 | 0.93 | DRD2 (0.58) | HRH3MAPTL3MBTL1CRHBPCRHR2 | |
| SCHEMBL10409901 | 0.91 | PTGS2 (0.62) | HRH3MAPTL3MBTL1CRHBPCRHR2 | |
| SCHEMBL6390929 | 0.91 | PPARD (0.53) | HRH3MAPTL3MBTL1CRHBPCRHR2 | |
| SCHEMBL9750517 | 0.91 | PTGS2 (0.62) | HRH3MAPTL3MBTL1CRHBPCRHR2 | |
| SCHEMBL10336456 | 0.91 | PTGS2 (0.62) | HRH3MAPTL3MBTL1CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-03-06 | — | — | US | disclosed |
| US-20240285777-A1 | INHIBITORS OF TTBK1 | THE GENERAL HOSPITAL CORPORATION | 2024-08-29 | — | — | US | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| US-5516767-A | PRODRUG AS HYPOGLYCEMIC AGENT | SANDOZ LTD. (CH) | 1996-05-14 | — | — | US | disclosed |
| US-5412137-A | Hypoglycemic agents | SANDOZ LTD. (CH) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | NCOR2, NSD2, NCOR1 | HRH3 3277/4885MAPT 2156/4885L3MBTL1 2832/4885 |
| US-20240285777-A1 | INHIBITORS OF TTBK1 | TTBK1, TTBK2, TTK | HRH3 4075/4885MAPT 64/4885L3MBTL1 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.